Histone lysine specific demethylase 1 inhibitors.
Samir MehndirattaJing Ping LiouPublished in: RSC medicinal chemistry (2020)
LSD1 plays a pivotal role in numerous biological functions. The overexpression of LSD1 is reported to be associated with different malignancies. Over the last decade, LSD1 has emerged as an interesting target for the treatment of acute myeloid leukaemia (AML). Numerous researchers have designed, synthesized, and evaluated various LSD1 inhibitors with diverse chemical architectures. Some of these inhibitors have entered clinical trials and are currently at different phases of clinical evaluation. This comprehensive review enlists recent research developments in LSD1 targeting pharmacophores reported over the last few years.
Keyphrases
- clinical evaluation
- clinical trial
- acute myeloid leukemia
- bone marrow
- liver failure
- cell proliferation
- dna methylation
- immune response
- transcription factor
- dendritic cells
- randomized controlled trial
- cancer therapy
- intensive care unit
- gene expression
- acute lymphoblastic leukemia
- drug induced
- allogeneic hematopoietic stem cell transplantation
- extracorporeal membrane oxygenation